Janus Henderson Group
DSGN icon

Janus Henderson Group’s Design Therapeutics DSGN Stock Holding History

Janus Henderson Group’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-829,425
Closed -$5.23M – 2568
2023
Q2 		$5.23M Sell
829,425
-14,293
-2% -$87.5K ﹤0.01% 851
2023
Q1 		$4.87M Sell
843,718
-262,141
-24% -$1.96M ﹤0.01% 881
2022
Q4 		$11.3M Sell
1,105,859
-1,901,763
-63% -$25.8M 0.01% 694
2022
Q3 		$50.3M Buy
3,007,622
+1,924,782
+178% +$38.3M 0.02% 516
2022
Q2 		$15.2M Sell
1,082,840
-35,711
-3% -$482K 0.01% 614
2022
Q1 		$18.1M Buy
1,118,551
+181,784
+19% +$2.78M 0.01% 768
2021
Q4 		$19.1M Buy
936,767
+108
+0% +$1.85K 0.01% 799
2021
Q3 		$13.1M Buy
936,659
+9
+0% +$150 0.01% 866
2021
Q2 		$17.7M Sell
936,650
-249,986
-21% -$6.31M 0.01% 818
2021
Q1 		$32.7M Buy
+1,186,636
New +$40M 0.01% 662

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group's DSGN Position: Q3 2023 in Review

Janus Henderson Group sold out of Design Therapeutics (DSGN) in Q3 2023, closing a stake of 829,425 shares — an estimated $5.23M sold.

Janus Henderson Group first reported a position in DSGN in Q1 2021 and held it in 10 quarters. The position peaked at $50.3M in Q3 2022. 87 funds tracked by Wall St. Rank hold DSGN as of Q3 2023.

  • Janus Henderson Group reported no remaining Design Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Janus Henderson Group sold 829,425 Design Therapeutics shares in Q3 2023, an estimated $5.23M.
  • Janus Henderson Group first reported a position in Design Therapeutics in Q1 2021 and held it in 10 quarters.
  • Janus Henderson Group's Design Therapeutics position peaked at $50.3M in Q3 2022.
  • 87 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2023.

Based on Janus Henderson Group's 13F filing for Q3 2023, filed 14 Nov 2023.